VSIG8抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Mouse heart tissue and KB cell lysates, Primary antibody: P02002(VSIG8 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P02002(VSIG8 Antibody) at dilution 1/240. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P02002(VSIG8 Antibody) at dilution 1/240. (Original magnification: ×200)    

  
  

The V-set and immunoglobulin domain-containing protein 8 (VSIG8) is a transmembrane protein belonging to the immunoglobulin superfamily (IgSF). It is primarily expressed in specific tissues, including the testis and certain immune cells. VSIG8 has garnered interest due to its structural features, such as extracellular V-set and Ig-like domains, which suggest roles in cell-cell interactions and immune regulation. Although its precise biological functions remain under investigation, VSIG8 is hypothesized to participate in immune modulation, potentially influencing T-cell activity or serving as a checkpoint molecule in immune responses.

VSIG8 antibodies are tools developed to detect, quantify, or inhibit VSIG8 in experimental settings. These antibodies enable researchers to study VSIG8's expression patterns, localization, and interactions in healthy and diseased tissues. Recent studies highlight its potential relevance in cancer immunology, where VSIG8 may contribute to tumor immune evasion, akin to other checkpoint proteins like PD-1/PD-L1. Antibodies targeting VSIG8 could thus have therapeutic applications, such as enhancing anti-tumor immunity.

Despite progress, the functional mechanisms of VSIG8 remain partially unresolved. Current research focuses on elucidating its ligands, signaling pathways, and tissue-specific roles. VSIG8 antibodies are critical reagents in these efforts, supporting both basic research and translational studies aimed at exploring VSIG8 as a biomarker or therapeutic target in immune-related disorders.